Welcome To Cellens

Sensing Cancer
on a Nanoscale Level

Bringing clarity and precision to cancer diagnostics through mechanobiology and machine learning

WHAT WE ARE DOING

Touching cancer cells with a nanoscale finger

Cellens is pioneering a novel diagnostic modality based on single cell biophysical markers. By touching cells at the nanoscale level, we uncover unique physical fingerprints of cancer cells that are ideal for accurate and non-invasive cancer detection.

0 +
Bladder cancer patients undergo routine BC monitoring
0 %
Estimated recurrence rate of bladder cancer after treatment

A NONINVASIVE, URINE-BASED CANCER DIAGNOSTICS PLATFORM

Octosense Platform

Cellens platform is scalable and applicable to different types of cancer cells, extracted from bodily fluid to detect various clinical conditions. Our peer-reviewed, preliminary data highlights the superior performance of our platform to achieve high accuracy in detecting bladder cancer.

1. Proprietary Cell Fixation

2. Urine Sample Processing

3. Cell Surface Scanning

4. Machine Learning Analysis

WHO WE ARE

Meet the Cellens Team

We know what it takes to bring physical touch to cancer diagnostics.

Our team brings expertise in mechanobiology, mechanical engineering, and innovation commercialization, and we are supported by an extensive network of scientific and industry advisors.

WHO WE ARE

Our Specialties

Cellens is pioneering in label-free cell analysis with a combination of high-resolution nanoscale imaging and proprietary machine learning. Our novel application of quantitative cell’s

Bio-Related Research

Bio-Related Research

Bio-Related Research

Bio-Related Research

WHO WE ARE

Our Partners

News

Publications & News

News
Springboard Enterprises Announces Inaugural 2024 Healthca...
The 2024 Accelerator Program Features Nine Women Driving Transformational Health SolutionsWASHINGTON, DC, UNITED STATES, Septem...
News
Cellens Announces Collaboration with Bruker BioAFM to Adv...
BOSTON–(BUSINESS WIRE)–Cellens, Inc., an early-stage cancer diagnostic company pioneering in applying mechanob...
News
LabCentral, a crucial incubator for local drug discovery,...
For the past year, Jean Pham and a pair of employees at her three-year-old company, Cellens, shared high-tech research instrume...
News
CELLENS IS ON SOSV HUMAN HEALTH 100 LIST
Welcome to the second annual SOSV Human Health 100. The list captures  SOSV’s 100 most exciting companies in human health ...
News
CELLENS WON GOLDEN TICKET IGNITE AWARD
CAMBRIDGE, Mass., Oct. 5, 2022 /PRNewswire/ — LabCentral Ignite, with support from key sponsors Pfizer, Br...
Publication
2021 | ATOMIC FORCE MICROSCOPY DETECTS THE DIFFERENCE IN ...
A novel method based on atomic force microscopy (AFM) working in Ringing mode (RM) to distinguish between two similar human col...
Publication
2018 | NONINVASIVE DIAGNOSTIC IMAGING USING MACHINE-LEARN...
We report an approach in diagnostic imaging based on nanoscale-resolution scanning of surfaces of cells collected from body flu...
Publication
2009 | AFM DETECTS DIFFERENCES IN THE SURFACE BRUSH OF NO...
The atomic force microscope is broadly used to study the morphology of cells but it can also probe the mechanics of cells. It i...
News
CELLENS & TUFTS UNIVERSITY TO RECEIVE “BITS TO BYTES”...
Fourteen projects receiving funding to support R&D, innovation in addressing challenges in therapeutic delivery and unlocki...